Ralph Mazitschek

Former Director-Chemistry Platform at The Massachusetts General Hospital

Ralph Mazitschek

Ralph Mazitschek

Former Director-Chemistry Platform at The Massachusetts General Hospital

Biography

Founder of Acetylon Pharmaceuticals, Inc. and TetraLogic Research & Development Corp., Ralph Mazitschek is former Director-Chemistry Platform at The General Hospital Corp. Dr. Mazitschek received a graduate degree from the University of Karlsruhe and a doctorate from Universität Leipzig.

Overview
Career Highlights

Acetylon Pharmaceuticals, Inc.
TetraLogic Research & Development Corp.

RelSci Relationships

1154

Number of Boards

1

Relationships
RelSci Relationships are individuals Ralph Mazitschek likely has professional access to. A relationship does not necessarily indicate a personal connection.

Scientific Founder at C4 Therapeutics, Inc.

Relationship likelihood: Strong

Chief, Division of Hematologic Neoplasia at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Co-Founder at C4 Therapeutics, Inc.

Relationship likelihood: Strong

Professor of Pathology & Laboratory Medicine at University of Pennsylvania - Perelman School of Medicine

Relationship likelihood: Strong

Professor of Pharmacology & Cancer Biology at Duke University - School of Medicine

Relationship likelihood: Strong

President & Chief Executive Officer at Acetylon Pharmaceuticals, Inc.

Relationship likelihood: Strong

Advisory Partner at NewSpring Capital

Relationship likelihood: Average

Former President at Lenel Systems International, Inc.

Relationship likelihood: Average

Chief Financial Officer, Secretary & Treasurer at Leap Therapeutics, Inc.

Relationship likelihood: Average

Vice President, CMC at Eloxx Pharmaceuticals, Inc.

Relationship likelihood: Average

Paths to Ralph Mazitschek
Potential Connections via
Relationship Science
You
Ralph Mazitschek
Former Director-Chemistry Platform at The Massachusetts General Hospital
Education

Universitt Leipzig was founded in 1409 and is thus the second oldest university in Germany where teaching has continued without interruption. Today it offers a wide spectrum of academic disciplines at 14 faculties with more than 150 institutes. From A for African Studies to W for West Slavic Studies, Universitt Leipzig is a classic university with the whole range of subjects from natural sciences through law, human and veterinary medicine to numerous arts degrees. 28,000 young people from all over the world are currently studying on more than 140 courses. A variety of co-operation programmes with foreign partner universities and an internationally oriented choice of subjects make Leipzig attractive for students world-wide. The University has exchange programmes with over 350 ERASMUS partner universities in some 150 European cities and with more than 60 universities outside Europe.

Memberships
Associate Member
Current

The Broad Institute evolved from a decade of informal and successful research collaborations among scientists in the MIT and Harvard communities. In 1990, the Whitehead Institute/MIT Center for Genome Research (WICGR) was founded, and it soon became an international leader in the field of genomics and a flagship of the Human Genome Project. As early as 1995, WICGR scientists recognized the need to bring the power of genomics to the understanding of human disease. It launched pilot projects in genomic medicine, forming an unofficial collaborative network among scientists from across MIT and Harvard who pioneered new approaches to cancer and human genetics. In parallel, Harvard Medical School-based scientists established the Institute of Chemistry and Cell Biology (ICCB) in 1998, to facilitate the pursuit of chemical genetics as an academic discipline and a tool to further understand human biology and disease. In 2002, the ICCB was awarded an Initiative for Chemical Genetics (ICG) grant from the National Cancer Institute, and its successful Investigator-Initiated Screening Program facilitated small molecule screening projects for more than 80 research groups worldwide. These projects demonstrated the power of enabling scientists to collaborate to tackle the major challenges in molecular medicine. It was clear that a new type of formal organization was required — open, collaborative, interdisciplinary, and able to organize projects at any scale. In addition, it was important that the complementary expertise of the genomic scientists and the chemical biologists across MIT and Harvard be brought together in one place to drive the transformation of medicine with molecular knowledge. Discussions in 2002-2003 among Eli and Edythe Broad, MIT, Harvard and its affiliated hospitals, and the Whitehead Institute shaped the vision for this new institute. The extraordinary generosity of Eli and Edythe Broad, through their founding gift of $100 million (later doubled to $200 million) made it possible to formally announce the new institute in June 2003 and to launch it in May 2004. Less than four years after its launch, the Broads gave an unprecedented gift of $400 million in September 2008 to permanently endow the institute, providing long-term sustainability for its unique model of collaborative, inter-institutional research.

Career History
Co-Founder
2008 - Prior

Acetylon Pharmaceuticals, Inc. develops pharmaceutical technology. It develops novel small molecule drugs which targets epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The company was founded by Ralph Mazitschek, Kenneth C. Anderson, Marc A. Cohen, James E. Bradner, and Walter C. Ogier in October 2008 and is headquartered in Boston, MA.

Co-Founder
Prior

TetraLogic Research & Development Corp. develops SHP-141 topical HDAC inhibitor clinical development for cutaneous T cell lymphoma. Its currently conducting a randomized, double-blind, placebo controlled, phase 1b study, to evaluate the safety and tolerability of SHP-141 in patients with stage 1A, 1B or 2A CTCL. The company was founded by James E. Bradner and Ralph Mazitschek in 2008 and is headquartered in Cambridge, MA.

Director-Chemistry Platform
Prior

Since 1811, Massachusetts General Hospital has been committed to delivering standard-setting medical care. Throughout the decades, the hospital has had a consistent commitment to advancing that care through pioneering research and educating future health care professionals. The third oldest general hospital in the United States and the oldest and largest hospital in New England, Mass General continues its tradition of excellence today. On July 17, 2012, Mass General was named America's best hospital by U. S. News & World Report based on our quality of care, patient safety and reputation in 16 different specialties. In 2008, Mass General was redesignated a Magnet hospital, the highest honor for nursing excellence awarded by the American Nurses Credentialing Center. World-Class Patient Care Our 907-bed medical center, located in the heart of Boston, offers sophisticated diagnostic and therapeutic care in virtually every specialty and subspecialty of medicine and surgery. We offer high-quality care and services in four health centers in the Boston area. The hospital also holds concurrent Level 1 verification for adult and pediatric trauma and burn care. Our five multidisciplinary care centers – known worldwide for innovations in cancer, digestive disorders, heart disease, transplantation and vascular medicine – unite specialists across the hospital to offer patients comprehensive, state-of-the-art medical care. In addition, through MassGeneral Hospital for Children, we provide a full range of pediatric health care services, from primary care to cutting-edge treatments of complex and rare disorders. A Research Powerhouse Mass General has long been a leader in successfully bridging innovative science with state-of-the-art clinical medicine. With an annual research budget of nearly $764 million, Mass General conducts the largest hospital-based research program in the United States - a program that spans more than 20 clinical departments and centers across the hospital. This funding drives discoveries and breakthroughs in basic and clinical research, which translate into new and better treatments that transform medical practice and patient care. Learn more about Mass General research. An Emphasis on Teaching Mass General is the original and largest teaching hospital of Harvard Medical School, where nearly all of our staff physicians serve on the faculty. Since the hospital’s founding, Mass General has been committed to training and mentoring the next generation of international leaders in science and medicine, providing a wealth of opportunities for physicians, nurses, allied health professionals, physical, occupational and speech and language therapists and other health professionals. These talented men and women, in turn, lend fresh and innovative perspective on how to treat and care for patients. See medical residency and fellowship opportunities at Mass General. Setting the Bar for Quality & Safety Safety, effectiveness, patient centeredness, timeliness, efficiency and equity – these six tenets established by the Institute of Medicine are the foundation of our approach to quality and safety. We measure our performance, set high goals and track our progress toward those goals. We compare ourselves against local and national benchmarks in key quality and safety areas to ensure we deliver the highest quality and safest care possible. Learn more about our quality and patient-safety programs. Reaching Out to the Community Our work has always been guided by the needs of patients and their families. Mass General partners with communities to build, improve and sustain health care delivery and increase the health and well-being of those who live and work and these communities. Read about how Mass General is making a difference locally and globally. At our main campus and four health centers in Charlestown, Chelsea, Revere and the North End, Mass General annually: Admits 47,000 inpatients Handles nearly 1.4 million outpatient visits Records 88,000 emergency room visits Performs 38,000 operations Delivers 3,600 babies Mass General is a founding member of Partners HealthCare, an integrated health care delivery system that includes the two founding academic medical centers, community hospitals, primary care and specialty physicians, specialty facilities, community health centers and other health-related entities. Our Mission Guided by the needs of our patients and their families, we aim to deliver the very best health care in a safe, compassionate environment; to advance that care through innovative research and education; and to improve the health and well-being of the diverse communities we serve

Boards & Committees
Member, Scientific Advisory Board
Current

Acetylon Pharmaceuticals, Inc. develops pharmaceutical technology. It develops novel small molecule drugs which targets epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The company was founded by Ralph Mazitschek, Kenneth C. Anderson, Marc A. Cohen, James E. Bradner, and Walter C. Ogier in October 2008 and is headquartered in Boston, MA.

Investments
Details Hidden

TetraLogic Research & Development Corp. develops SHP-141 topical HDAC inhibitor clinical development for cutaneous T cell lymphoma. Its currently conducting a randomized, double-blind, placebo controlled, phase 1b study, to evaluate the safety and tolerability of SHP-141 in patients with stage 1A, 1B or 2A CTCL. The company was founded by James E. Bradner and Ralph Mazitschek in 2008 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Ralph Mazitschek. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Ralph Mazitschek's profile does not indicate a business or promotional relationship of any kind between RelSci and Ralph Mazitschek.